Abcellera Biologics Inc
ABCL
View Detailed Chart
3.160USD
+0.380+13.67%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
944.88MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+13.67%
5 Days
-12.71%
1 Month
-18.97%
6 Months
-23.30%
Year to Date
-7.60%
1 Year
-3.95%
View Detailed Chart
TradingKey Stock Score of Abcellera Biologics Inc
Currency: USD Updated: 2026-02-06Key Insights
Abcellera Biologics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 108 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.83.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Abcellera Biologics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Abcellera Biologics Inc Highlights
StrengthsRisks
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.83M.
Fairly Valued
The company’s latest PE is -5.48, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 112.27M shares, decreasing 0.09% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 42.69K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.75.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
9.833
Target Price
+253.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Abcellera Biologics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Abcellera Biologics Inc Info
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Ticker SymbolABCL
CompanyAbcellera Biologics Inc
CEOHansen (Carl L.G)
Websitehttps://www.abcellera.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70093.550
+123.420 (+0.18%)
282.580
+22.390 (+8.61%)
2079.780
+28.050 (+1.37%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
